Benjamin Besse

Benjamin Besse leads drug development at Institut Gustave Roussy and has been a principal investigator for numerous first-line immunotherapy trials in NSCLC, establishing European perspectives on PD-1/PD-L1 inhibitor combinations. His early-phase trial work has contributed to the development of multiple immunotherapy-based regimens and novel combinations in lung cancer. He has championed biomarker-driven patient selection strategies for immunotherapy in NSCLC. Besse's research group at Gustave Roussy is among the most prolific in thoracic oncology in Europe.